Immunophage Completes ￥100M Pre-A Round of Financing

According to PEdaily.cn, Nanjing Immunophage Biological Medicine Technology Co., Ltd. ("Immunophage") has closed its Pre-A round of nearly 100 million yuan, led by Jinfang Hongrui Investment, with participation from Nanjing Entan Ruiguang Healthcare Industry Investment, Zibo Jinfang Hengjian Equity Fund, Qingdao Zhongtai Huiyin Investment, Nanjing Yangzi Technology Venture Equity Fund and Nanjing Xinnong Yangzi Modern Agricultural Industry Development Fund.

Proceeds from the latest round is mainly used for the IND application reporting of Immunophage's two core pipelines and the early development of more than two new drugs.

Established in 2016, Immunophage focuses on the treatment of malignant tumors, autoimmune diseases and neurodegenerative diseases, and tries to develop new drugs from the aspects of immune regulation. The company has built several R&D pipelines. The R&D center of Immunophage is located in the Lingang Pujiang International Science and Technology City in Shanghai. 

Dr. Fan Guohuang, founder of Immunophage, said, "As a biopharmaceutical company with a short history, we must make full use of our advantages in the field of major diseases and discover new targets that are not available in the market, so as to have greater development space in the future. What we care more about is the innovation of the target and the new understanding of diseases."

All the research projects of Immunophage have competitive advantages and distinct characteristics, and all the anti-tumor projects have dual- or multi-targets. IPG1094, one of the products under development, not only inhibits tumor growth, but also inhibits the formation of targeted mediated myeloid inhibitory cells (MDSC), thus reversing the immunosuppressive tumor microenvironment. IPG7236, which is also under development, can not only inhibit tumor metastasis, but also inhibit the tumor infiltration of regulatory T cells.

In addition to the small molecule R&D projects, Immunophage also has pipelines of monoclonal antibodies and dual anticancer drugs. The company also explore in the fields of multiple myeloma, solid tumors and peripheral neuralgia after chemotherapy.